Contributors

Contributors

Profile Picture

Dr.Joseph Rosado

Dr. Joseph Rosado is one of the United States’ most well-respected scientists working with Medical Cannabis. He has been regularly featured on major US TV networks as a guest speaker. Dr. Rosado is fluent in English and Spanish. Further, he has been invited to speak all over the world educating doctors including but not limited to these countries: Fiji, Malaysia, Italy, and Costa Rica.

Website: https://josephrosadomd.com

Phone number: +1 (866) 763-7991

Ketamine Cystitis and Sexual Dysfunction in Women: A 2011 Case-Control Study

Introduction In a significant study published in BJU International on December 16, 2011, Jang et al. examined the relationship between ketamine cystitis (KC) and sexual dysfunction in women. This research offers valuable insights into the broader impact of chronic ketamine use on female patients’ quality of life, emphasizing the importance of multidisciplinary care. Key Points Study Design This case-control study involved women diagnosed with ketamine cystitis compared to a control group without urinary symptoms. Standardized surveys assessed sexual function, focusing on dimensions like desire, arousal, pain, and satisfaction. Results Women with ketamine cystitis reported significantly higher rates of sexual dysfunction. Key findings included: Increased pain during intercourse (dyspareunia). Decreased sexual desire and overall satisfaction. The study suggests that bladder pain and associated symptoms may contribute to psychological and physiological barriers to sexual health. Clinical Implications Ketamine cystitis extends beyond urological symptoms, necessitating a holistic approach to patient care. Providers should consider routine sexual health assessments in women with KC to address potential concerns early. Broader Impact As ketamine use continues to grow in medical and recreational contexts, awareness of its long-term effects is crucial for prevention and intervention. The VitalPoint For Providers This study underscores the need for healthcare professionals to adopt an integrative approach when treating women with ketamine cystitis. Regularly screening for sexual dysfunction and offering interdisciplinary support—combining urology, gynecology, and mental health services—can significantly improve patient outcomes. Relevance to Providers: This research provides actionable data to help clinicians identify and address an often-overlooked aspect of care for women with ketamine-related bladder dysfunction. Further Reading: Original study on BJU International Ketamine cystitis management guidelines

January 2, 2025
Understanding How Ketamine Use Can Affect Women's Health: Insights from a 2011 Study

Introduction A groundbreaking study published in 2012 explored the connection between ketamine use and sexual health in women. Conducted by Jang et al. and published in BJU International on December 16, 2011, this research sheds light on how long-term ketamine use, known to cause bladder issues like ketamine cystitis, can also impact a woman's intimate life. Key Points What is Ketamine Cystitis? Ketamine cystitis (KC) is a condition linked to chronic ketamine use, causing bladder pain, frequent urination, and other urinary issues. Study Details The research involved two groups of women: those with ketamine cystitis and a control group without it. Participants completed surveys on their sexual health, focusing on issues like pain, satisfaction, and libido. Findings Women with ketamine cystitis were more likely to report sexual dysfunction. Specific challenges included pain during intercourse, reduced sexual desire, and lower satisfaction. These issues may stem from the physical and emotional toll of bladder pain and urinary symptoms. Why This Matters Sexual health is a vital part of overall well-being. Recognizing these challenges can help women seek appropriate care and support. The VitalPoint For Patients If you or someone you know is dealing with ketamine use or bladder issues, understanding how these problems may affect sexual health is essential. This study highlights the importance of seeking medical advice for urinary symptoms and discussing any related concerns with a healthcare provider. Relevance to Patients: This research encourages open conversations about sexual and bladder health and emphasizes that help is available. Learn More: Read about ketamine cystitis and treatment options Find support resources for sexual health

January 2, 2025
Ketamine and Women's Health: What You Need to Know (March 2023 Report)

Introduction This March 2023 study by Jong BE, Chang SJ, Li CH, and Yang SS explored how ketamine use may affect sexual and bladder health in women. Ketamine is sometimes used recreationally, but it’s important to understand how it could impact the body, especially in areas that might not be immediately obvious. Key Points Ketamine and Bladder Issues: Long-term use of ketamine has been linked to bladder dysfunction. This includes symptoms like frequent urination, difficulty holding urine, and even pain during urination. Impact on Sexual Health: The researchers found that women using ketamine often experience sexual dysfunction, including a decrease in sexual desire, discomfort during intercourse, and challenges with arousal. Connection Between Issues: The study revealed that bladder and sexual dysfunction might be closely related. For instance, women with severe bladder symptoms were more likely to report sexual difficulties. Underlying Causes: These effects could result from ketamine's impact on the nervous system, bladder, and surrounding tissues, which are interconnected. The VitalPoint for Patients If you or someone you know uses ketamine, it's crucial to understand the risks. This study highlights that ketamine isn't just about short-term effects; it can significantly harm bladder and sexual health. These changes may affect daily life and relationships. If you’re experiencing symptoms, talk to a healthcare provider about possible treatments or alternatives. Relevant Links: Full Study Abstract Ketamine’s Effects on Health (NIH)

January 2, 2025
Ketamine and Chronic Pain: Insights from Medical Cannabis to Psychedelics (2023, Project CBD)

Introduction This 2023 feature from Project CBD examines a patient’s journey from federally approved medical cannabis use to integrating ketamine into their pain management regimen. It provides insight into ketamine’s emerging role as a versatile adjunct in managing chronic pain and mood disorders. Key Points Patient-Centric Challenges: A federal medical marijuana patient highlights gaps in cannabis access and quality that necessitated exploring alternative therapies like ketamine. Pharmacodynamics of Ketamine: Ketamine’s NMDA receptor antagonism disrupts pain signaling and supports neuroplasticity, distinguishing it from traditional opioids and cannabinoids. Clinical Relevance: Evidence supports ketamine’s efficacy in acute and chronic pain, particularly neuropathic pain, and its utility in addressing comorbid conditions such as treatment-resistant depression. Evolving Paradigms: The report situates ketamine within a broader conversation on the limitations of federal medical marijuana programs and the need for integrative pain management solutions. Summary – The VitalPoint for Providers Ketamine represents a promising, evidence-based option for managing chronic pain and psychiatric comorbidities. Healthcare providers should remain informed about ketamine protocols, potential risks, and its role in multimodal treatment frameworks. Explore more in the detailed analysis at Project CBD: Project CBD: MMJ to Special K https://projectcbd.org/psychedelic/mmj-special-k/

MMJ to Special K: Exploring Ketamine and Chronic Pain Relief (2023, Project CBD)

Introduction In this 2023 report from Project CBD, the narrative of a federal medical cannabis patient reveals how ketamine—a powerful, fast-acting dissociative anesthetic—has become a critical tool for managing chronic pain. The piece explores the evolving role of ketamine as an alternative treatment, particularly in the context of limitations surrounding medical marijuana. Key Points Patient Story: A federal medical marijuana patient describes their transition to using ketamine for pain relief after cannabis alone became insufficient. Why Ketamine? Ketamine’s benefits include rapid pain relief and its unique mechanism of action, which targets NMDA receptors and influences neural pathways associated with pain and mood regulation. Barriers to Cannabis Access: Despite federal approval for specific patients, the restricted availability and inconsistent quality of medical marijuana forced the search for supplementary treatments. Ketamine in Medicine: The article underscores how ketamine has gained acceptance in managing severe chronic pain and mental health conditions like depression, PTSD, and anxiety. Summary – The VitalPoint for Patients Ketamine could provide a transformative option for chronic pain sufferers who face challenges with medical cannabis or other traditional treatments. Patients should consult with their healthcare provider to explore its appropriateness and consider its potential as part of a broader pain management strategy. For more, visit the detailed article on Project CBD: Project CBD: MMJ to Special K. https://projectcbd.org/psychedelic/mmj-special-k/

Scroll to Top